Program in Evidence-based Care
Full Text Guideline
Evidence Supporting the Recommendations
The recommendations are supported by systematic reviews, randomized controlled trials (RCTs), and other studies.
Implementation of the Guideline
An implementation strategy was not provided.
Quick Reference Guides/Physician Guides
Benefits/Harms of Implementing the Guideline Recommendations
The performance of fecal immunochemical test (FIT) is superior to the standard guaiac fecal occult blood test (gFOBT) in terms of screening participation rates and the detection of colorectal cancer (CRC) and advanced adenoma (AA).
False-positive and false-negative results
Rating Scheme for the Strength of the Recommendations
- The use of fecal immunochemical test (FIT) is associated with greater specimen instability for both time between stool sampling and kit processing (according to the manufacturer's inserts, only three of the examined FITs are stable for ≥7 days, and only two are stable for ≥15 days) and temperature (two studies reported an association between lower temperatures and longer stability). FIT may also be associated with higher positivity rates than is standard guaiac fecal occult blood test (gFOBT). Three studies found higher positivity rates associated with FIT, two of which were statistically significantly higher, while only one of the studies found significantly higher positivity rates associated with gFOBT, in a comparison between the FIT and a high sensitivity gFOBT. Therefore, any screening program considering the use of FIT needs to take these factors into account.
- Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way.
Searches of Electronic Databases
The MEDLINE and EMBASE databases were systematically searched for articles assessing fecal immunochemical test (FIT) screening for colorectal cancer (CRC) published between 1996 and indexed through June 2010. The search strategies used are listed in Appendix D in the original guideline document. Additionally, the websites of a large number of agencies and organizations were also searched for evidence, and a listing of all sources searched and the number of articles ordered and retained appears in Table 2 in the original guideline document. Expert Panel members were also canvassed to ensure that no relevant articles were missed.
In addition to the evidence obtained in this review, the knowledge obtained from the ColonCancerCheck Program will be considered when making recommendations.
Eligible sources of information had to meet the following criteria:
- Published full reports with information on any of performance, usability, or specimen stability factors as listed above
- Systematic reviews (SRs), randomized controlled trials (RCTs), other prospective study designs, retrospective study designs, and mixed design studies. For the purpose of this paper, systematic reviews including those that are the evidentiary foundation for clinical practice guidelines or health technology assessments, or similar reports were included, provided that they reported in detail (e.g., search methods, selection criteria) on a systematic search and summary of the health care literature for articles on a relevant topic.
- Reports published in English
- Reports evaluated at least one FIT kit that is licensed by Health Canada for use in Canada.
- Reports excluded symptomatic participants.
A total of eleven papers were retained, comprising two systematic reviews, five papers reporting on three randomized controlled trials (RCTs), and papers regarding four other studies.
Expert Consensus (Committee)
Systematic Review with Evidence Tables
Quality Assessment of Included Evidence
An assessment of study quality was performed for all the included evidence. For randomized controlled trials (RCTs), no specific instrument was used, but items such as randomization, sample size estimates and power calculation, and funding sources were reported on. The Expert Panel recognizes that, due to the nature of the studies being examined, blinding to the intervention was not always possible, and therefore the lack of blinding was not considered a methodological flaw, nor was lack of a reported period of follow-up.
For the other evidence types, the Quality Assessment of Studies of Diagnostic Accuracy included in Systematic Reviews (QUADAS) tool was used where appropriate. The QUADAS tool is a 14-item questionnaire intended to assess primary studies of diagnostic utility for systematic reviews. The QUADAS instrument can only be used to assess studies of diagnostic utility where one test is compared with another (typically, the gold standard). For diagnostic studies without a comparator, no formal quality assessment was planned.
Development and Internal Review
This Evidence-Based Series (EBS) report was developed by the Fecal Immunochemical Test (FIT) Guidelines Expert Panel. The series is a convenient and up-to-date source of the best available evidence on three clinical issues related to FIT, developed through systematic review, expert consensus, evidence synthesis, and input from practitioners and colorectal cancer (CRC) screening experts. Section 2 in the original guideline document contains the systematic review of the evidence. The draft guidelines derived from the interpretation of that evidence and the expertise of the members of the Panel are detailed in Section 1 in the original guideline document. Sections 1 and 2 were circulated to health care providers, colorectal cancer screening experts and others in Ontario for their feedback. Section 3 in the original guideline document presents the feedback process results and any changes made to the draft document.
A formal cost analysis was not performed and published analyses were not reviewed.
External Peer Review
Internal Peer Review
Internal Review: Program in Evidence-based Care (PEBC) Director
Prior to the External Review (ER) of this Evidence-Based Series (EBS) draft report, it was submitted for Internal Review on March 9, 2011 to the Director of the PEBC, Dr. Melissa Brouwers, a researcher with expertise in methodological issues. The document was approved, pending changes, by Dr. Brouwers on March 15, 2011.
External Review: Targeted Peer Review (TPR)
Beginning on May 9, 2011, the PEBC Director-approved document was distributed to individuals in Canada with relevant expertise as part of the TPR process. It must be noted that the ER consisted of standardized survey questions that are used for all PEBC guidelines; therefore, some of the included questions regarding the recommendations are not fully relevant to this specific guideline. The survey was completed on June 20, 2011, and the results were analyzed. A total of seven individuals were invited to participate, and a total of seven submitted responses (100% response rate).
Expert Panel Response: Targeted Peer Review
Upon completion of the ER procedure, the Expert Panel reviewed the results of the TPR portion. The EBS was well received, and none of the TPR respondents rated the document as being of low quality or strongly disagreed with the findings. The majority of respondents rated the quality of the document high or highest and agreed with the findings.
External Review: Professional Consultation (PC)
Beginning on May 9, 2011, the PEBC Director-approved document was distributed to individuals within the Province of Ontario with relevant expertise as part of a PC review process. It must be noted that the ER questions in the survey used for all PEBC guidelines are standardized; therefore, some of the included questions regarding the recommendations are not fully relevant to this specific guideline. The survey was completed on June 20, 2011 and the results were analyzed. A total of 262 individuals were invited to participate (a total of 253 received the survey to complete), and a total of 107 submitted responses (42.3% response rate).
Expert Panel Response: Professional Consultation
Upon completion of the ER procedure, the Expert Panel reviewed the results of the PC portion. Generally, the EBS was well-received although some respondents did rate the quality low or lowest and disagreed or strongly disagreed with the findings. However, the majority of the respondents did report the document being of good or high quality and agreed or strongly agreed with the findings. Regarding the comments received, the Expert Panel agrees with the majority of the feedback obtained and will take these comments into consideration moving forward. The Expert Panel agrees with the barriers and enablers identified in the External Review and will take them into consideration moving forward.
Identifying Information and Availability
Rabeneck L, Rumble RB, Thompson F, Mills M, Oleschuk C, Whibley AH, Messersmith H, Lewis N, FIT Guidelines Expert Panel. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Toronto (ON): Cancer Care Ontario (CCO); 2011 Nov 8. Various p. (Evidence-based series; no. 15-8). [44 references]
Not applicable: The guideline was not adapted from another source.
The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.
The Program in Evidence-based Care (PEBC) is a provincial initiative of Cancer Care Ontario. It is supported by the Ontario Ministry of Health and Long-Term Care through Cancer Care Ontario. All work produced by the PEBC is editorially independent from its funding source.
Fecal Immunochemical Test (FIT) Guidelines Expert Panel
Panel Members: Linda Rabeneck, MD, MPH, FRCPC (Chair), Vice President, Prevention and Cancer Control Cancer Care Ontario, Toronto, ON; R. Bryan Rumble, MSc, Research Coordinator, Cancer Care Ontario's Program in Evidence-based Care, Department of Oncology, McMaster University, Hamilton, ON; Frank Thompson, MD, Midland, ON; Michael Mills, MD, CCFP, FCFP, Regional Primary Care Lead, Hamilton Niagara Haldimand Brant LHIN, Cancer Care Ontario, Juravinski Regional Cancer Centre, Hamilton, ON; Curtis Oleschuk, MD, FCACB, Clinical Biochemist, Department of Clinical Biochemistry and Genetics, Diagnostic Services of Manitoba, Winnipeg, MB; Alexandra Whibley, BSc(Hons), Project Coordinator, Cancer Care Ontario, Toronto, ON; Hans Messersmith, MPH, Assistant Director, Quality and Methods, Program in Evidence-Based Care, Cancer Care Ontario, McMaster University, Hamilton, ON; Nancy Lewis, PhD, Senior Policy and Planning Officer, Cancer Care Ontario, Toronto, ON
This is the current release of the guideline.
The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.
Please visit the Cancer Care Ontario Web site for details on any new evidence that has emerged and implications to the guidelines.
Electronic copies: Available in Portable Document Format (PDF) from the Cancer Care Ontario Web site.
The following are available:
- Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Summary. Toronto (ON): Cancer Care Ontario (CCO); 2011 Nov 8. 5 p. Electronic copies: Available in Portable Document Format (PDF) from the Cancer Care Ontario (CCO) Web site.
- Program in Evidence-Based Care (PEBC) handbook. Toronto (ON): Cancer Care Ontario (CCO); 2012. 14 p. Electronic copies: Available in PDF from the CCO Web site.
This NGC summary was completed by ECRI Institute on September 6, 2013.
This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please refer to the Copyright and Disclaimer Statements posted at the Program in Evidence-based Care section of the Cancer Care Ontario Web site.
Colorectal cancer (CRC)
- To evaluate the existing evidence concerning fecal immunochemical test (FIT) to inform the decision on how to replace the current guaiac fecal occult blood test (gFOBT) with a FIT in Ontario's ColonCancerCheck Program
- To evaluate what the performance characteristics (sensitivity, specificity, positivity, and positive predictive value [PPV]) of FIT are when used to detect colorectal cancer (CRC)
- To evaluate what FIT kit factors affect acceptability by users (e.g., card versus vial collection FIT, medication use)
- To evaluate what factors affect specimen stability
Men and women at average risk for colorectal cancer (CRC) (i.e., asymptomatic, 50 years of age and older, and with no other risk factors for CRC)
Fecal immunochemical test (FIT)
- Performance characteristics including sensitivity, specificity, positivity, and positive predictive value (PPV)
- User acceptability
- Specimen stability
- The Fecal Immunochemical Test (FIT) Guidelines Expert Panel recommends that a pilot study be performed to investigate how to implement FIT in the population-based colorectal cancer (CRC) screening program in Ontario. This pilot study should evaluate FIT based on laboratory, field, and economic factors. The laboratory component would evaluate specimen stability under varying conditions and the feasibility of automation. The field component would evaluate kit distribution, labelling of kits, stool sampling, and transportation of completed kits to the laboratory. An economic evaluation would be included.
- Any program implemented should use automated kit labelling (e.g., bar code) and not require a separate requisition for the kit.
Institute of Medicine (IOM) National Healthcare Quality Report Categories
The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion-criteria.aspx.
NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.